Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citranvi EBV vaccine
- Development stage
- Preclinical
- Lead developer
- Citranvi Biosciences
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Citranvi Biosciences is developing a multiantigen protein-based vaccine for the prevention of Epstein-Barr virus (EBV) infection. The vaccine utilizes a proprietary herpesvirus protein multimeric technology platform licensed from the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). This platform produces recombinant proteins in a multimeric form to enhance the induction of protective neutralizing antibodies. The vaccine targets multiple EBV envelope proteins, specifically gH/gL, gB, and gp350, which are critical for viral entry into host cells. It is intended to prevent EBV-associated diseases, including infectious mononucleosis and various EBV-associated cancers. The program is currently in preclinical development in collaboration with the Uniformed Services University of the Health Sciences (USU) and the U.S. Department of Defense.
- Other names
- EBV vaccinemultiantigen EBV vaccine
02
Targets
gB (Human cytomegalovirus glycoprotein B)gp350 (Epstein-Barr virus glycoprotein 350)EBV gH/gL (Epstein-Barr virus glycoprotein H/glycoprotein L complex)gp42 (Epstein-Barr virus glycoprotein 42)
Beyond the preview
Go deeper on Citranvi EBV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citranvi EBV vaccine.